NCT07532148

Study of CKD-215 and D215 in Adults With BRCA-mutated Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

A Multicenter, Randomized, Open-Label, 2-Period Crossover Study to Evaluate Pharmacokinetics, Safety, and Tolerability of CKD-215 and D215 in Adults With Advanced BRCA-Mutated Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

• Status: Not Yet Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 24 (estimated)
• Sponsor: Chong Kun Dang Pharmaceutical · Industry
• Sex: Female
• Age: 19 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

Clinical Trial to evaluate the pharmacokinetic Characteristics, safety and Tolerability among CKD-215 and D215

Detailed description

A Multi-center, Randomized, Open-Label, Multiple-dose, Two-Stage, Two-treatment, Two-period, Crossover Study

Conditions

• Ovarian Cancer

Interventions

Type	Name	Description
DRUG	CKD-215	2 tablets BID at 12-hour intervals for 7 days
DRUG	D215	2 tablets BID at 12-hour intervals for 7 days

Timeline

• Start date: 2026-06-01
• Primary completion: 2027-06-01
• Completion: 2027-08-01
• First posted: 2026-04-15
• Last updated: 2026-04-15